Статья
Телмисартан в комплексной терапии артериальной гипертензии: от фармакологических особенностей к клиническим преимуществам
Настоящая статья посвящена вопросам фармакологических особенностей и преимуществ использования антагониста рецепторов ангиотензина II телмисартана в реальной клинической практике. Данный бифункциональный представитель класса блокаторов рецепторов ангиотензина II первого типа обладает рядом уникальных фармакокинетических особенностей: наибольшей продолжительностью действия, высокой степенью липофильности и максимальной эффективностью в отношении активации рецепторов PPARγ. Представлены результаты многочисленных исследований, подтверждающих высокую эффективность телмисартана и способность контролировать АД в течение суток и ранние утренние часы в сравнении с другими антигипертензивными препаратами. Основные плеойтропные свойства телмисартана доказаны на большинстве этапов кардиоваскулярного и ренального континуумов, главными из которых являются снижение инсулинорезистентности, повышение уровня адипонектина, улучшение функциональной активности эндотелия, ангио и ренопротективные эффекты и способность обеспечивать регресс гипертрофии миокарда левого желудочка. Доказана способность телмисартана влиять на прогноз у пациентов высокого сердечно-сосудистого риска и обеспечивать снижение летальности и количества сердечно-сосудистых осложнений. Опираясь на данные масштабных исследований, рассмотрены возможности использования телмисартана 80 мг/сутки, в том числе, в сочетании с гидрохлоротиазидом, как наиболее мощной двойной фиксированной комбинации и одной из основных современных стратегий антигипертензивной терапии.
1. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;23(6):7-122. doi:10.15829/1560-4071-2018-6-7-122.
2. Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors 2020 and Beyond. Journal of the American College of Cardiology Volume 74, Issue 20, 19 November 2019, Pages 2529-2532. doi: 10.1016/j.jacc.2019.10.009.
3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23. doi:10.1016/s0140-6736(05)70151-3.
4. Чазова И. Е., Жернакова Ю. В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31. doi:10.26442/2075082X.2019.1.190179.
5. Galzerano D, Capogrosso C, Di Michele S, et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010;6:113-33. doi:10.2147/VHRM.S7857.
6. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637-45. doi:10.1016/s0140-6736(99)10365-9.
7. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension.Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.
8. Burnier M. Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension. Drugs. 2002;62(1):21-9.
9. Kakuta H, Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: Comparison with other angiotensin II type 1 receptor blockers Int. J Clin Pharmacol Res. 2005;25(1):41-6.
10. Stangier J, Su CA, Roth W. Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive Patients. J Int Med Res. 2000;28(4):149-67 doi:10.1177/14732300000280040.
11. Li L, Luo Z, Yu H, et al. Telmisartan Improves Insulin Resistance of Skeletal Muscle Through Peroxisome Proliferator-Activated Receptor-б Activation. Diabetes. 2013;62(3):762-74. doi:10.2337/db12-0570.
12. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR — modulating activity. Hypertension. 2004;43:993-1002. doi:10.1161/01.HYP.0000123072.34629.57.
13. White WB, Giles T, Bakris GL, et al. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006;151(1):176-84. doi:10.1016/j.ahj.2005.02.014.
14. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: Impact on the early morning period. Am J Hypertension. 2004;17(4):347-53. doi:101016/j.amjhyper.2004.02.016.
15. Nishimura T, Hashimoto J, Ohkubo T, et al. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens. 2005;27(6):477-89. doi:10.1081/CEH-200067668.
16. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4:90-8. doi:10.1016/j.jash.2010.03.001.
17. Rea F, Corrao G, Merlino L, et al. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39(40):3654-61. doi:10.1093/eurheartj/ehy420.
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97. doi:10.1001/jama.288.23.2981.
19. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The RENAAL Study Investigation. N Engl J Med. 2001;345:861-9. doi:10.1056/NEJMoa011161.
20. Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010;8(6):793-802. doi:10.1586/erc.10.27.
21. Lacourciere Y, Tytus R, O'Keefe D, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens. 2001;15(11):763-70. doi:10.1038/sj.jhh.1001267.
22. Kjeldsen SE, Schumacher H, Neldam S, et al. Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients. J Clin Hypertens (Greenwich). 2013;15(6):380-8. doi:10.1111/jch.12089.
23. Neutel JM, Littlejohn TW, Chrysant SG, et al. Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-tomoderate hypertension. Hypertens Res. 2005;28:555-63. doi:10.1291/hypres.28.555.
24. Siragusa M, Sessa WC. Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival. Arterioscler Thromb Vasc Biol. 2013 August; 33(8): doi:10.1161/ATVBAHA.112.300985.
25. Wago T, Yoshimoto T, Akaza I, et al. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. Hypertens Res. 2010;33(8):796-801. doi: 10.1038/hr.2010.107.
26. Perl S, Schmolzer I, Sourij H, еt al. Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance. Int J Cardiol. 2010;139(3):289-96. doi:101016/j.ijcard.2008.10.048.
27. Benndorf RA, Appel D, Maas R, et al. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol. 2007;50(4):367-71. doi :10.1097/FJC.0b013e31811dfbe7.
28. Kinouchi K, Ichihara A, Sakoda M, et al. Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. Kidney Blood Press. Res. 2010;33(4):304-12. doi:101159/000316724.
29. Hasegawa H, Takano H, Narumi H, et al. Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. Hypertens Res. 2011;34(11):1179-84. doi:10.1038/hr.2011.114.
30. Yamaguchi K, Wakatsuki T, Soeki T, et al. Effects of telmisartan on inflammatory cytokines and coronary plaque component as assessed on integrated backscatter intravascular ultrasound in hypertensive patients. Circ J. 2014;78(1):240-7. doi:10.1253/circj.cj-13-0741.
31. Yusuf S, Teo K, Anderson C, et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a 43. randomised controlled trial. Lancet. 2008;372(9644):1174-83. doi:101016/S0140-6736(08)61242-8.
32. Diener HC, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release 44. dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and 45. placebo-controlled study. Lancet Neurol. 2008;7(10):875-84. doi: 10.1016/S1474-4422(08)70198-4.
33. Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. 46. Hypertension Research. 2009;32:826-34. doi:10.1038/hr.2009.135.
34. Liu Y, Vu V, Sweeney G. Examining the Potential of Developing and Implementing Use of Adiponectin-Targeted Therapeutics for Metabolic and Cardiovascular Diseases. 47. Front Endocrinol. 2019 11 December; doi:10.3389/fendo.2019.00842.
35. Taguchi I, Inoue T, Kikuchi M, et al. Pleiotropic effects of ARB on dyslipidemia. Curr Vasc Pharmacol. 2011;9(2):129-35. doi:10.2174/157016111794519336.
36. Takagi H, Niwa M, Mizuno Y, et al. ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Telmisartan as a metabolic sartan: the first meta-analysis 48. of randomized controlled trials in metabolic syndrome. J Am Soc Hypertens. 2013;7(3):229-35. doi:10.1016/j.jash.2013.02.006.
37. Sharma AM, Davidson J, Koval S, et al. Telmisartan/hydrochlorothiazide versus valsartan/ hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: 49. the SMOOTH study. Cardiovasc Diabetol. 2007;6:28. doi:10.1186/1475-2840-6-28.
38. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356(9227):366-72. doi:10.1016/S0140-6736(00)02527-7.
39. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an attihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366:895-906. doi:10.1016/S0140-6736(05)67185-1.
40. Barnett AH. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetol. 2005;42 Suppl 1:S42-9. doi:10.1007/s00592-005-0180-4.
41. Makino H, Haneda M, Babazono T, et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy-rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. J Int Med Res. 2005 Nov-Dec;33(6):677-86. doi:10.1177/147323000503300610.
42. Galle J, Schwedhelm E, Pinnetti S; VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 2008 Oct;23(10):3174-83. doi:10.1093/ndt/gfn230.
43. Bakris G, Burgess E, Weir M, et al. AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 Aug;74(3):364-9. doi:10.1038/ki.2008.204.
44. Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 4;359(23):2417-28. doi:10.1056/NEJMoa0806182.
45. Katholi RE, Couri DM. Left Ventricular Hypertrophy: Major Risk Factor in Patients with Hypertension: Update and Practical Clinical Applications. International J Hypertens. 2011 :Article ID 495349. doi: 10.4061/2011/495349.
46. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59. doi:10.1056/NEJMoa0801317.
47. Mizuguchi Y, Oishi Y, Miyoshi H, et al. Telmisartan improves morphologic and functional changes in both left ventricular myocardium and carotid arterial wall in patients with hypertension: assessment by tissue Doppler imaging and carotid ultrasonography. Echocardiography. 2010;27(7):864-72. doi: 10.1111/j.1540-8175.2010.01163.x.
48. Mizuguchi Y, Oishi Y, Miyoshi H, et al. Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging. J Hypertens. 2009;27(9): 1892-9. doi: 10.1097/HJH.0b013e32832d8785.
49. Takagi H, Mizuno Y, Iwata K, et al. Blood pressure-independent effects of telmisartan on regression of left ventricular mass: a meta-analysis and meta-regression of randomized controlled trials 2012. Int J Cardiol. 2013 May 25; 165(3):564-7. doi:10.1016/j.ijcard.2012.09.044.
50. Fogari R, Zoppi A, Maffioli P, et al. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. Clin Cardiol.2012;35(6):359-64. doi:10.1002/clc.21994.
51. Galzerano D, Di Michele S, Paolisso G, et al. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. J Renin Angiotensin Aldosterone Syst. 2012;13(4):496-503. doi:10.1177/1470320312443909.
52. Du H, Fan J, Ling Z, et al. Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients. Hypertension. 2013;61(4):786-92. doi:10.1161/HYPERTENSIONAHA.111.202309.
53. Pan G, Zhou X, Zhao J. Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and metaanalysis. Cardiovasc Ther. 2014;32(4):184-8. doi:10.1111/1755-5922.12073.
54. Ruilope LM. Telmisartan for the management of patients at high cardiovascular risk. Journal Current Medical Research and Opinion. 2011;27(8):1673-82.
55. Инструкция по медицинскому применению лозартана, ирбесартана, валсартана, кандесартана, олмесартана, азилсартана, телмисартана.